Evelo Biosciences, along with Rutgers University and Robert Wood Johnson University Hospital, is driving toward a Phase II study of an investigational treatment for hospitalized patients with newly diagnosed COVID-19.
The company is aiming a drug initially under development for psoriasis at COVID-19 based on early clinical data that shows its efficacy in blunting the production of multiple inflammatory cytokines – the same kind that many serious COVID-19 patients are dealing with.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,